

Development of a novel polyherbal product for treatment of Atopic dermatitis & other chronic dermal inflammatory diseases

16th European Dermatology Congress June 07-08, 2017 Milan, Italy




Dr Anu T. Singh

Vice President (R&D) Dabur Research Foundation, INDIA

1



Collaborative Drug Development : Inflammatory Skin Diseases



SIRB-001 – Product properties





- A polyherbal product for a wide range of skin diseases
- Fully characterized
- Potent anti-inflammatory
- Clinically validated targets
- Found to be safe for human use
- Tested on over 150 patients
- IP-Over 50 patents filed
- Received provisional clearance for EU

commercialization




Scope of SIRB 001

No.	Formulation	Indication	
1	Cream	Psoriasis, Eczema, Atopic dermatitis	
2	Shampoo - 1	Scalp Psoriasis	
3	Hair lotion	Scalp psoriasis	
4	Hair Serum / vitalizer	Seborrhoea / Dandruff	
5	Shampoo - 2	Seborrhoea / Dandruff	
6	Acne Gel	Acne	
7	NanoGel	Psoriasis, Eczema, Atopic dermatitis	
8	Oral Tablets	Psoriasis, other chronic inflammatory disorders	
9	Oral Nanoparticles	Psoriasis, other chronic inflammatory disorders	4



The journey so far...



Atopic Dermatitis



- Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis).
- It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thicken over time.
- In children under one year of age much of the body may be affected. In adults the hands and feet are the most commonly affected areas.
- The cause is unknown but believed to involve genetics, immune system dysfunction, environmental exposures, and difficulties with the permeability of the skin.
- The pathophysiology may involve a mixture of type I and type IV-like hypersensitivity reactions.








Etiology of AD



- Atopic dermatitis (AD) is a chronic inflammatory disease which results from complex interactions between genetic and environmental mechanisms.
- An altered lipid composition of the stratum corneum is responsible for the xerotic aspect of the skin and determines a higher permeability to allergens and irritants.
- Keratinocytes of AD patients exhibit a propensity to an exaggerated production of cytokines and chemokines, a phenomenon that can have a major role in promoting and maintaining inflammation.
- Dendritic cells expressing membrane IgE receptors play a critical role in the amplification of allergen-specific T cell responses.
- Thymus And Activation Regulated Chemokine (TARC) -CCR4 ligand, overexpressed in eczema lesions and attracts Th2 cells.
- A complex network of cytokines and chemokines contributes to establishing a local milieu that favors the permanence of inflammation in AD skin.



J. Clin. Invest.2004;113:651-657


7

Atopic dermatitis: mechanism of disease

https://www.slideshare.net/AllergyChula/atopicdermatitis-mechanism-of-disease



Treatment



Medscape, 2008



Limitations of current AD treatment options


Treatment	Limitation	
Topical corticosteroids	 Long-term use can lead to skin atrophy, spider veins, stretch marks, and pigmentation abnormalities Rarely in extreme cases, may cause hypothalamic-pituitary-adrenal suppression, leading to Cushing's syndrome 	
Oral immunosuppressive drugs	 Systemic oral immunosuppressive drugs, such as cyclosporine are often coupled with serious side effects; skin damage, thinned or weakened bones, high blood pressure, high blood sugar, infections etc. 	
Biologics	 Side effects include flu-like symptoms such as chills, fever, muscle aches, weakness, loss of appetite, nausea vomiting, and diarrhea High cost 	
Phototherapy	 Possible long-term side effects of this treatment include premature skin aging and skin cancer 	

http://www.medicinenet.com/atopic_dermatitis/page10.htm

9










Biologics in Atopic Dermatitis

JAK-kinase inhibitors in AD

- Janus-Kinases (JAK) are involved in cell signaling pathways activated by cytokines.
- Tofacitinib, a JAK kinase inhibitor has emerged as new therapeutics for severe, recalcitrant Atopic Dermatitis.



Biologics in AD


Emerging treatments for atopic dermatitis

Therapy	Therapy Mechanism of action				
Biologics					
CIM331	Antibody against IL-31 receptor	2			
ILV-094	Antibody against IL-22	2			
Tralokinum ab	Antibody against IL-23	2			
Ustekinum ab	Antibody against IL-12 & IL-23	2			
Dupilumab	Antibody against IL-4 receptor	3			
Anti-pruritics					
СТ327	Tropomyosin receptor kinase A inhibitor	2			
VLY-686	Neurokinin 1 receptor antagonist	2			

SIRB 001 - The Product




- A novel mixture of 3 herbs; *Rheum palmatum* L. (Da Huang), *Rehmannia glutinosa* Libosch (Sheng di huang) and *Lonicera Japonica* (Jin yin hua) was developed in the ratio 1:1:3.
- Fingerprinting analysis performed by HPLC with 3 marker compounds Chlorogenic acid, Acteoside and Rhein.
- SIRB 001 has been demonstrated to work as anti proliferative immunopotentiating product. It down regulates key proinflammatory cytokines including TNF alpha, IL17/IL23
- SIRB 001 has shown potential for treatment of chronic dermal inflammatory diseases including psoriasis, Eczema & others





Anti-AD potential of SIRB 001-Preclinical studies





450

400

350

300

250

200


150

100

50

(Jm/6d) 9-7(

In vitro Anti-AD potential of SIRB-001



IL-6


3 3.4

TNF-a (10 ng/ml)


Curcumin (PC)

4.2 5 6

SIRB-001 (mg/ml)




Nitric Oxide



Significant downregulation of inflammatory cytokines; TNF- α (80%-85%), IFN- γ (44%-72%), IL-6 (12%-50%) and Nitric Oxide (25%-50%) in keratinocytes (HaCaT)




In vitro Anti-AD potential of SIRB-001




Significant downregulation of chemokine-TARC (38%-100%) and VEGF (40%-92%) in keratinocytes (HaCaT)



In vitro Anti-AD potential of SIRB-001






- Significant downregulation of IL-6 (20%-60%) in immune cells (macropahges)
- IgE inhibition (20%-60%) in human myeloma cell line; U-266



In vitro Anti-AD potential of SIRB-001




- Inhibition of JANUS KINASES - JAK-1/JAK-3 (10%-75%)

17



Anti-AD potential of SIRB-001 – Mechanism of action






SIRB-001- Safety

Extensive studies carried out in animals have demonstrated SIRB-001 safe for topical and oral administration

- Acute and sub acute Safety studies
- Chronic safety studies 6 months
- Mutagenecity
- Reproductive safety
- Skin sensitization
- In vitro HetCAM & 3-D skin studies
- Safety pharmacology






Therapeutic potential of SIRB 001 in other chronic skin inflammatory diseases




Anti psoriatic potential of SIRB 001






SIRB 001 – Unifying MoA in inflammatory skin disorders






Patient stratification for SIRB-001 - Strategy





Patient stratification for SIRB-001

- Serum samples collected from 30 patients at 2 time points (baseline and completion of treatment) were analysed for 27 inflammatory markers associated with psoriasis using Multiplex technology.
- Serum samples were also collected from
 7 healthy volunteers to evaluate the markers elevated in disease condition.
- Levels of 7 markers was found to be elevated (> 1.5 fold) in disease condition as compared to healthy controls.
- Down regulation (>20%) was observed in 6 markers upon treatment with SIRB-001 cream for 56 weeks.





Searching for prognostic markers for SIRB 001....

Inhibition of markers Day 56 vs. Day-0



Biomarkers vs % Inhibition in Biomarker levels in patients after treatment (D56 VS D0)

% Decrease = (Mean value Day 0-Mean value Day 56)x100/Mean value Day 0



Highlights of clinical trial results

Indication	Site	Number of subjects	Evidence of clinical efficacy
Psoriasis	Cermany	21	
Scalp psoriasis	CITER HITEHRIDINAL SE DE VELOPPEMENT PHARMACEUTIQUE India	30	
Eczema	CITER WITHWINGHALEW DEVELOPPEMENT PHARMACEUTIQUE India	30	
Seborrhoea	CIVIE HOTHWINGHAR EVELOPEEMENT PHARMACEUTIOUE India	30	
Atopic dermatitis	Germany	25	
Acne	CONTRACTOR OF THE OFFICE OFFIC	30	





13TH EADV SPRING SYMPOSIUM 19-22 MAY 2016 ATHENS, GREECE



PSORIASIS 2016 PARIS, 7-9 JULY 2016

5th CONGRESS OF THE PSORIASIS INTERNATIONAL NETWORK

Evaluation of anti-psoriatic potential of a novel polyherbal formulation by multiparametric analysis

Anti-psoriatic potential and safety of a novel polyherbal formulation

conferenceseries.com 7th European Dermatology Congress



June 13-14, 2016 Alicante, Spain

Development of a novel polyherbal topical product for the management of eczema & other chronic dermal inflammatory conditions International Conference on **Psoriasis and Skin Specialists Meeting**

December 08- 09, 2016 Dallas, Texas, USA

Development of a novel polyherbal topical formulation for the management of psoriasis



THANKS